Preventive effect of halofuginone on concanavalin A-induced liver fibrosis

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Liang, Jie ^a   Zhang, Bei ^a   Shen, Ruo Wu ^a   Liu, Jia Bao ^a   Gao, Mei Hua ^a   Li, Ying ^a   Li, Yuan Yuan ^a   Zhang, Wen ^a  

^a QINGDAO UNIVERSITY MEDICAL COLLEGE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA SMOOTH MUSCLE ACTIN; ASPARTATE AMINOTRANSFERASE; COLLAGEN TYPE 1; CONCANAVALIN A; HALOFUGINONE; HYALURONIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROCOLLAGEN; PROCOLLAGEN TYPE 3; SMAD3 PROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE ASSOCIATION; DISEASE SEVERITY; DOWN REGULATION; DRUG EFFICACY; DRUG STRUCTURE; HISTOPATHOLOGY; LIVER FIBROSIS; LIVER HISTOLOGY; LIVER PROTECTION; MALE; MOLECULAR DYNAMICS; NONHUMAN; PROTEIN DETERMINATION; PROTEIN FUNCTION; RAT; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; TISSUE LEVEL;

ALANINE TRANSAMINASE; ANIMALS; ASPARTATE AMINOTRANSFERASES; CONCANAVALIN A; DRUGS, CHINESE HERBAL; INTERLEUKIN-1BETA; INTERLEUKIN-6; LIVER CIRRHOSIS; MALE; PIPERIDINES; QUINAZOLINONES; RATS, WISTAR; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84892761497     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0082232     Document Type: Article

References (51)

1. Perepelyuk M, Terajima M, Wang AY, Georges PC, Janmey PA, et al. (2013) Hepatic stellate cells and portal fibroblasts are the major cellular sources of collagens and lysyl oxidases in normal liver and early after injury. Am J Physiol-gastr L 304: G605-G614
2. Iredale JP (1997) Tissue inhibitors of metalloproteinases in liver fibrosis. Int J Biochem Cell Biol 29: 43-54. doi:10.1016/S1357-2725(96)00118-5. PubMed: 9076940.
3. Birkedal-Hansen H, Moore WG, Bodden MK, Windsor LJ, Birkedal-Hansen B et al. (1993) Matrix metalloproteinases: a review. Crit Rev Oral Biol M 4: 197-250. PubMed: 8435466.
4. Moon SK, Linthicum FH Jr, Dong Yang H, Joo Lee S, Park K (2008) Activities of matrix metalloproteinases and tissue inhibitor of metalloproteinase-2 in idiopathic hemotympanum and otitis media with effusion. Acta Oto-Laryngol 128: 144-150. doi: 10.1080/00016480701477610. PubMed: 17851959.
5. Friedman SL (2008) Mechanisms of hepatic fibrogenesis. Gastroenterology 134: 1655-1669. doi:10.1053/j.gastro.2008.03.003. PubMed: 18471545.
6. Bansal R, Prakash J, Post E, Beljaars L, Schuppan D et al. (2011) Novel engineered targeted interferon?gamma blocks hepatic fibrogenesis in mice. Hepatol 54: 586-596. doi:10.1016/j.jhep.2010.09.012.
7. Clària J (2012) Natural killer cell recognition and killing of activated hepatic stellate cells. Gut 61: 792-793. doi:10.1136/gutjnl-2011- 301968. PubMed: 22466617.
8. Venugopal SK, Jiang J, Kim T-H, Li Y, Wang S-S, et al. (2010) Liver fibrosis causes downregulation of miRNA-150 and miRNA-194 in hepatic stellate cells, and their overexpression causes decreased stellate cell activation. Am J Physiol-gastr L 298: G101-G106
9. Liu C, Tao Q, Sun M, Wu JZ, Yang W et al. (2010) Kupffer cells are associated with apoptosis, inflammation and fibrotic effects in hepatic fibrosis in rats. Lab Invest 90: 1805-1816. doi:10.1038/labinvest.2010.123. PubMed: 20921949.
10. Thabut D, Routray C, Lomberk G, Shergill U, Glaser K et al. (2011) Complementary vascular and matrix regulatory pathways underlie the beneficial mechanism of action of sorafenib in liver fibrosis. Hepatology 54: 573-585. doi:10.1002/hep.24427. PubMed: 21567441.
11. Jagavelu K, Routray C, Shergill U, O'Hara SP, Faubion W et al. (2010) Endothelial cell toll-like receptor 4 regulates fibrosis-associated angiogenesis in the liver. Hepatol 52: 590-601. doi:10.1002/hep.23739.
12. Derynck R, Zhang YE (2003) Smad-dependent and Smad-independent pathways in TGF-β family signalling. Nature 425: 577-584. doi:10.1038/nature02006. PubMed: 14534577.
13. Wang C, Song X, Li Y, Han F, Gao S et al. (2013) Low-Dose Paclitaxel Ameliorates Pulmonary Fibrosis by Suppressing TGF-β1/Smad3 Pathway via miR-140 Upregulation. PLOS ONE 8: e70725. doi: 10.1371/journal.pone.0070725. PubMed: 23967091.
14. Gurantz D, Cowling RT, Varki N, Frikovsky E, Moore CD et al. (2005) IL-1β and TNF-α upregulate angiotensin II type 1 (AT〈sub〉 1〈/sub〉) receptors on cardiac fibroblasts and are associated with increased AT〈 sub〉 1〈/sub〉 density in the post-MI heart. J Mol Cell Cardiol 38: 505-515. doi:10.1016/j.yjmcc.2004.12.015. PubMed: 15733910.
15. Siwik DA, Chang DL-F, Colucci WS (2000) Interleukin-1β and tumor necrosis factor-α decrease collagen synthesis and increase matrix metalloproteinase activity in cardiac fibroblasts in vitro. Cir Res 86: 1259-1265. doi:10.1161/01.RES.86.12.1259.
16. Atamas SP (2002) Complex cytokine regulation of tissue fibrosis. Life Sci 72: 631-643. doi:10.1016/S0024-3205(02)02299-3. PubMed: 12467904.
17. Shahar I, Fireman E, Topilsky M, Grief J, Kivity S et al. (1996) Effect of IL-6 on alveolar fibroblast proliferation in interstitial lung diseases. Clin Immunol Immunopathol 79: 244-251. doi:10.1006/clin.1996.0075. PubMed: 8635282.
18. Wynn TA (2008) Cellular and molecular mechanisms of fibrosis. J Pathol 214: 199-210. doi:10.1002/path.2277. PubMed: 18161745.
19. Hayden MS, Ghosh S (2011) NF-κB in immunobiology. Cell Res 21: 223-244. doi:10.1038/cr.2011.13. PubMed: 21243012.
20. Ren Z, Cui J, Huo Z, Xue J, Cui H et al. (2012) Cordycepin suppresses TNF-α-induced NF-κB activation by reducing p65 transcriptional activity, inhibiting IκBα phosphorylation, and blocking IKKaγ ubiquitination. Int Immunopharmacol, 14: 698-703. PubMed: 23102662.
21. Sun B, Karin M (2008) NF-êB signaling, liver disease and hepatoprotective agents. Oncogene 27: 6228-6244. doi:10.1038/onc. 2008.300. PubMed: 18931690.
22. Elsharkawy AM, Mann DA (2007) Nuclear factor-ê2. Elsharkawy AM, Mann DA (200-fibrosis-cancer axis. Hepatol 46: 590-597. doi:10.1002/hep.21802.
23. Jaruga B, Hong F, Kim W-H, Sun R, Fan S, et al. (2004) Chronic alcohol consumption accelerates liver injury in T cell-mediated hepatitis: alcohol disregulation of NF-êB and STAT3 signaling pathways. Am J Physiol-gastr L 287: G471-G479
24. Luedde T, Schwabe RF (2011) NF-êB in the liver-linking injury, fibrosis and hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 8: 108-118. doi:10.1038/nrgastro.2010.213. PubMed: 21293511.
25. Xia Y, Chen J, Cao Y, Xu C, Li R et al. (2013) Wedelolactone exhibits anti-fibrotic effects on human hepatic stellate cell line LX-2. Eur J Pharmacol, 714: 105-11. PubMed: 23791612.
26. Nguyen-Pouplin J, Tran H, Tran H, Phan TA, Dolecek C et al. (2007) Antimalarial and cytotoxic activities of ethnopharmacologically selected medicinal plants from South Vietnam. J Ethnopharmacol 109: 417-427. doi:10.1016/j.jep.2006.08.011. PubMed: 17010546.
27. Gu Y-Y, Liu S-X, Wang S-X, Wan S-B, Jiang T (2011) Study on the Synthetic Technique of Halofuginone. Zhongguo Haiyang Daxue Xuebao Ziran Kexue Ban 9: 012.
28. Meindl-Beinker NM, Matsuzaki K, Dooley S (2012) TGF-β Signaling in Onset and Progression of Hepatocellular Carcinoma. Dig Dis 30: 514-523. doi:10.1159/000341704. PubMed: 23108308.
29. Pines M, Snyder D, Yarkoni S, Nagler A (2003) Halofuginone to treat fibrosis in chronic graft-versus-host disease and scleroderma. Biol Blood Marrow Transplant 9: 417-425. doi:10.1016/S1083-8791(03)00151-4. PubMed: 12869955.
30. Bruck R, Genina O, Aeed H, Alexiev R, Nagler A et al. (2001) Halofuginone to prevent and treat thioacetamide-induced liver fibrosis in rats. Hepatol 33: 379-386. doi:10.1053/jhep.2001.21408.
31. Benchetrit S, Yarkoni S, Rathaus M, Pines M, Rashid G, et al. (2007) Halufuginone reduces the occurrence of renal fibrosis in 5/6 nephrectomized rats. IMAJ-RAMAT GAN- 9: 30
32. Pines M, Nagler A (1998) Halofuginone: a novel antifibrotic therapy. Gen Pharmacol 30: 445-450. doi:10.1016/S0306-3623(97)00307-8. PubMed: 9522159.
33. Nelson EF, Huang CW, Ewel JM, Chang AA, Yuan C (2012) Halofuginone down-regulates Smad3 expression and inhibits the TGFbeta-induced expression of fibrotic markers in human corneal fibroblasts. Mol Vis 18: 479-487. PubMed: 22393274.
34. Leiba M, Cahalon L, Shimoni A, Lider O, Zanin-Zhorov A et al. (2006) Halofuginone inhibits NF-κB and p38 MAPK in activated T cells. J Leukoc Biol 80: 399-406. doi:10.1189/jlb.0705409. PubMed: 16769768.
35. Tiegs G, Lohse AW (2010) Immune tolerance: what is unique about the liver. J Autoimmun 34: 1-6. doi:10.1016/j.jaut.2009.08.008. PubMed: 19717280.
36. Itoh A, Isoda K, Kondoh M, Kawase M, Kobayashi M et al. (2009) Hepatoprotective effect of syringic acid and vanillic acid on concanavalin a-induced liver injury. Biol Pharm Bull 32: 1215-1219. doi: 10.1248/bpb.32.1215. PubMed: 19571388.
37. Richard S, Guerret S, Gerard F, Tebib JG, Vignon E (2000) Hepatic fibrosis in rheumatoid arthritis patients treated with methotrexate: application of a new semi-quantitative scoring system. Rheumatology 39: 50-54. doi:10.1093/rheumatology/39.1.50. PubMed: 10662873.
38. Schwabe RF, Brenner DA (2006) Mechanisms of liver injury. I. TNF-α- induced liver injury: role of IKK, JNK, and ROS pathways. Am J Physiol-gastr L 290: G583-G589
39. Pines M, Knopov V, Genina O, Lavelin I, Nagler A (1997) Halofuginone, a specific inhibitor of collagen type I synthesis, prevents dimethylnitrosamine- induced liver cirrhosis. J Hepatol 27: 391-398. doi: 10.1016/S0168-8278(97) 80186-9. PubMed: 9288615.
40. Watanabe A, Kobayashi M, Hayashi S, Kodama D, Isoda K et al. (2006) Protection against D-galactosamine-induced acute liver injury by oral administration of extracts from Lentinus edodes mycelia. Biol Pharm Bull 29: 1651-1654. doi:10.1248/bpb.29.1651. PubMed: 16880621.
41. Park SY, Shin HW, Lee KB, Lee M-J, Jang J-J (2010) Differential expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in thioacetamide-induced chronic liver injury. J Korean Med Sci 25: 570-576. doi:10.3346/jkms.2010.25.4.570. PubMed: 20358000.
42. Ruiz-Ortega M, Rodríguez-Vita J, Sanchez-Lopez E, Carvajal G, Egido J (2007) TGF-β signaling in vascular fibrosis. Cardiovasc Res 74: 196-206. doi:10.1016/j.cardiores.2007.02.008. PubMed: 17376414.
43. Moustakas A, Pardali K, Gaal A, Heldin C-H (2002) Mechanisms of TGF-β signaling in regulation of cell growth and differentiation. Immunol Lett 82: 85-91. doi:10.1016/S0165-2478(02)00023-8. PubMed: 12008039.
44. Schultz GS, Wysocki A (2009) Interactions between extracellular matrix and growth factors in wound healing. Wound Repair Regen 17: 153-162. doi:10.1111/j.1524-475X.2009.00466.x. PubMed: 19320882.
45. Nakamura T, Sakata R, Ueno T, Sata M, Ueno H (2000) Inhibition of transforming growth factor β prevents progression of liver fibrosis and enhances hepatocyte regeneration in dimethylnitrosamine-treated rats. Hepatol 32: 247-255. doi:10.1053/jhep.2000.9109.
46. Yin M, Jin S, Cui H (2012) Effect of chymase inhibitors on dimethylnitrosamine-induced rat liver fibrosis and on chymase and collagen I expression. Afr - J Pharm and Pharmaco 6: 2870-2874.
47. McGaha TL, Phelps RG, Spiera H, Bona C (2002) Halofuginone, an Inhibitor of Type-I Collagen Synthesis and Skin Sclerosis, Blocks Transforming-Growth- Factor-β-Mediated Smad3 Activation in Fibroblasts. J Invest Dermatol 118: 461-470. doi:10.1046/j.0022-202x.2001.01690.x. PubMed: 11874485.
48. Xavier S, Piek E, Fujii M, Javelaud D, Mauviel A et al. (2004) Amelioration of radiation-induced fibrosis inhibition of transforming growth factor-β signaling by halofuginone. J Biol Chem 279: 15167-15176. doi:10.1074/jbc.M309798200. PubMed: 14732719.
49. Ghosh S, May MJ, Kopp EB (1998) NF-{kappa} B and Rel proteins: evolutionarily conserved mediators of immune responses. Sci Signal 16: 225.
50. Kopp E, Ghosh S (1994) Inhibition of NF-kappa B by sodium salicylate and aspirin. Science 265: 956-959. doi:10.1126/science.8052854. PubMed: 8052854.
51. Kopp EB, Ghosh S (1995) NF-κB and rel proteins in innate immunity. Adv Immunol 58: 1-27. doi:10.1016/S0065-2776(08)60618-5. PubMed: 7741027.